Algorae Pharmaceuticals (ASX:1AI) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Current Accrued Expense?

Algorae Pharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Algorae Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Algorae Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Current Accrued Expense Chart

Algorae Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

Algorae Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Algorae Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Algorae Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals (ASX:1AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

LVCLY:USA LVCLF:USA LHI0:Germany

Address

201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines